The human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in several breast and stomach malignancies, is the target of the monoclonal antibody trastuzumab. Trastuzumab works by inhibiting the development of cancer cells and enhancing the effectiveness of cancer treatment by specifically targeting HER2.
1. Trastuzumab is a crucial component of the treatment for HER2-positive breast cancer, whether it is in an advanced stage or has spread to other organs. It is frequently used after surgery or in conjunction with chemotherapy to lower the chance of cancer recurrence.
2. HER2-Positive Gastric Cancer: Trastuzumab is used in conjunction with chemotherapy to treat advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer.
3. Trastuzumab may also be employed in the treatment of other HER2-positive malignancies, subject to the particular circumstances and the oncologist's suggestion.
The phrase "lyophilized powder" designates a freeze-dried, powder version of the medication that needs to be reconstituted before administration. In a medical setting, it is often given intravenously (IV) by healthcare professionals.
Trastuzumab may induce adverse effects, which might vary depending on the patient and the precise treatment plan, as with any medication. Infusion responses, heart problems, weariness, and potential impacts on blood cell counts are examples of common adverse effects.
If you have questions about "Eleftha" (trastuzumab lyophilized powder) or any other medication that has been prescribed to you or someone you know, talk to a licenced healthcare professional right once. They can provide you with thorough information about the drug's functions, potential adverse effects, and how to administer it.